Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors.
A series of novel spirocyclic ethers were designed to function as nonpeptidal P2-ligands for HIV-1 protease inhibitors. Incorporation of designed ligands in the (R)-(hydroxyethylamino)sulfonamide isostere afforded potent HIV protease inhibitors.
Ghosh
A K
AK
Department of Chemistry, University of Illinois at Chicago 60607, USA.
Krishnan
K
K
Walters
D E
DE
Cho
W
W
Cho
H
H
Koo
Y
Y
Trevino
J
J
Holland
L
L
Buthod
J
J
D018360:Crystallography, X-Ray; D015195:Drug Design; D004988:Ethers, Cyclic / Q000138:chemical synthesis* / Q000737:chemistry* / Q000494:pharmacology; D016333:HIV Protease / Q000378:metabolism*; D017320:HIV Protease Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry* / Q000494:pharmacology; D015497:HIV-1 / Q000201:enzymology; D006801:Humans; D007700:Kinetics; D008024:Ligands; D008958:Models, Molecular; D008968:Molecular Conformation; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
D004988:Ethers, Cyclic; D017320:HIV Protease Inhibitors; D008024:Ligands; D016333:HIV Protease